Published: 2017-06-23

Evaluation of effectiveness of rupatadine and olopatadine in patients of allergic rhinitis at Indore: a randomized control trial

Jay Shah, Poonam Patel


Background: Allergic rhinitis (AR) is one of the most prevalent atopic disorders that affect productivity and quality of life. Although individually olopatadine and rupatadine are efficacious in AR, data on the head to head study of these drugs in Indian population are scanty, so present study was undertaken with an aim to compare the efficacy, safety, and cost effectiveness of rupatadine and olopatadine in patients’ of allergic rhinitis.

Methods: A prospective, randomized, double blind, parallel group, comparative 2 weeks clinical study conducted in eighty patients of AR in the Department of Pharmacology, Index Medical College Hospital and Research Centre, Indore. Following inclusion and exclusion criteria, 67 patients were recruited and randomized to two treatment groups and received the respective drugs for 2 weeks. At follow-up, parameters assessed were total nasal symptom score (TNSS), change in total and differential count of eosinophil.

Results: In olopatadine group, there was a significantly higher reduction in TNSS (P < 0.05) than that of rupatadine. Both the drugs significantly reduced the absolute eosinophil count, but olopatadine (P <0.001) was found to be superior. The incidence of adverse effects was found to be less in olopatadine group when compared with rupatadine group.

Conclusions: Both rupatadine and olopatadine provide effective relief of the symptoms of AR. However, clinical benefit occurs significantly more with olopatadine. However, rupatadine was more cost‑effective than olopatadine in treating the patients of AR in term of effectiveness.


Allergic rhinitis, Efficacy, Indore, Randomized

Full Text:



Maiti R, Rahman J, Jaida J, Allala U, Palani A. Rupatadine and levocetirizine for seasonal allergic rhinitis: A comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg. 2010;136:796‑800.

Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety. J Pharmacol Pharmacother. 2011;2:270‑6.

Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing‑Moore J, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81(5 Pt 2):478‑518.

Yamamoto H, Yamada T, Kubo S, Osawa Y, Kimura Y, Oh M, et al. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double‑blind, placebo‑controlled study. Allergy Asthma Proc. 2010;31:296‑303.

Enomoto T, Lu HQ, Yin M, Sakoda T, Dake Y, Enomoto K, et al. Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit. J Investig Allergol Clin Immunol. 2009;19:299‑305.

Mion Ode G, Campos RA, Antila M, Rapoport PB, Rosario N, de Mello Junior JF, et al. Futura study. Evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol. 2009;75:673‑9.

Valero A, Izquierdo I, Giralt J, Bartra J, del Cuvillo A, Mullol J. Rupatadine improves nasal symptoms, quality of life (ESPRINT‑15) and severity in a subanalysis of a cohort of Spanish allergic rhinitis patients. J Investig Allergol Clin Immunol. 2011;21:229‑35.

Kubavat AH, Pawar P, Mittal R, Sinha V, Shah UB, Ojha T, et al. An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. J Assoc Physicians India. 2011;59:424‑8.

Cohen DJ, Reynolds MR. Interpreting the results of cost‑effectiveness studies. J Am Coll Cardiol. 2008;52:2119‑26.

Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009;18:57‑68.

Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002;88:379‑97.

Miyake K, Ohmori K, Ishii A, Karasawa A. Short communication inhibitory effect of olopatadine hydrochloride (KW‑4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils. Allergol Int. 2001;50:113‑6.

Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K. Olopatadine suppresses the migration of THP‑1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006:42726.

Dakhale GN, Wankhede SS, Mahatme MS, Hiware SK, Mishra DB, Dudhgaonkar SS. Comparison of efficacy, safety and cost‑effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: A Randomized, Double‑blind, Comparative, Parallel Group Trial. Indian J Dermatol. 2016;61:63‑9.

Donado E, Izquierdo I, Pérez I, García O, Antonijoan RM, Gich I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: Results from a ‘thorough QT/QTc study’ performed according to ICH guidelines. Br J Clin Pharmacol. 2010;69:401‑10.